Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 7/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.64 |
| ▸ | HTR7 | P34969 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.54 |
| ▸ | THRA | P10827 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | STS | P08842 | 4/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7789291 | 0.98 | HSD17B3 (0.71) | HSD17B3HDAC1HDAC8HTR7HDAC3 | |
| SCHEMBL7789360 | 0.98 | HSD17B3 (0.71) | HSD17B3HDAC1HDAC8HTR7HDAC3 | |
| SCHEMBL4293741 | 0.98 | HSD17B3 (0.71) | HSD17B3HDAC1HDAC8HTR7HDAC3 | |
| SCHEMBL7907717 | 0.98 | HSD17B3 (0.71) | HSD17B3HDAC1HDAC8HTR7HDAC3 | |
| SCHEMBL7788804 | 0.98 | HSD17B3 (0.71) | HSD17B3HDAC1HDAC8HTR7HDAC3 | |
| SCHEMBL1091479 | 0.94 | HSD17B3 (0.69) | HSD17B3HDAC1HDAC8HTR7HDAC3 | |
| SCHEMBL19757444 | 0.93 | HSD17B3 (0.65) | HSD17B3HDAC1HDAC8HTR7HDAC3 | |
| SCHEMBL18753070 | 0.90 | HSD17B3 (0.84) | HSD17B3HTR7THRATHRBSTS | |
| SCHEMBL133319 | 0.90 | HDAC1 (0.75) | HSD17B3HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL9341720 | 0.89 | HDAC1 (0.64) | HSD17B3HDAC1HDAC8HTR7HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116444458-A | Method for realizing migration of remote aromatic heterocycle and direct alkyl heteroaryl of terminal olefin | 南京工业大学 | 2023-07-18 | — | — | CN | disclosed |
| US-8003678-B2 | Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds | ALLERGAN, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003678-B2 | Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds | ALLERGAN, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-7964596-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964596-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7781465-B2 | Therapeutic oxazolidinones and thiazolidinones | ALLERGAN, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781465-B2 | Therapeutic oxazolidinones and thiazolidinones | ALLERGAN, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100093809-A1 | THERAPEUTIC SUBSTITUTED THIAZOLIDINONES, OXAZOLIDINONES, AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093809-A1 | THERAPEUTIC SUBSTITUTED THIAZOLIDINONES, OXAZOLIDINONES, AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7659295-B2 | 5-(3-(3-(4-(1-hydroxyhexyl)phenyl)-4-oxo-thiazolidin-2-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agents; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | ALLERGAN, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20080045596-A1 | Ep2 Receptor Agonists | ASTERAND, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045596-A1 | Ep2 Receptor Agonists | ASTERAND, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045596-A1 | Ep2 Receptor Agonists | ASTERAND, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080033023-A1 | Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted pyrrolidine compounds | OLD DAVID W | 2008-02-07 | — | — | US | disclosed |
| EP-1716113-A1 | EP2- RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2006-11-02 | — | — | EP | disclosed |
| US-20050209336-A1 | EP2 receptor agonists | ASTERAND, INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005061449-A1 | EP2 RECEPTOR AGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
| US-6191182-B1 | SUBJECTING P-HALOPHENYL ALKYL KETONE TO AMINOLYSIS WITH CYCLIC SECONDARY AMINE TO FORM CYCLIC AMINE-SUBSTITUTED PHENYL ALKYL KETONE; HALOGINATION AND REACTING WITH AMINE COMPOUND; STEVENS REARRANGEMENT UNDER BASIC CONDITION | CIBA SPECIALTY CHEMCIALS CORPORATION | 2001-02-20 | — | — | US | disclosed |
| US-5977357-A | Phenyl alkyl ketone substituted by cyclic amine and a process for the preparation thereof | CIBA SPECIALTY CHEMICAL CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| US-5795985-A | Phenyl alkyl ketone substituted by cyclic amine and a process for the preparation thereof | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1998-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209336-A1 | EP2 receptor agonists | PTGER2, PTGER1, PTGER3 | HSD17B3 1111/4885HDAC1 1450/4885HDAC8 916/4885 |
| US-20100093809-A1 | THERAPEUTIC SUBSTITUTED THIAZOLIDINONES, OXAZOLIDINONES, AND RELATED COMPOUNDS | THPO, MT-ND4L, ABAT | HSD17B3 882/4885HDAC1 153/4885HDAC8 276/4885 |
| US-20080033023-A1 | Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted pyrrolidine compounds | PTGER2, PTGS2, PTGIS | HSD17B3 1563/4885HDAC1 1163/4885HDAC8 1448/4885 |
| US-20080045596-A1 | Ep2 Receptor Agonists | PTGER2, PTGER1, PTGER3 | HSD17B3 1111/4885HDAC1 1450/4885HDAC8 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.